Finally, our inspiring Sussex Cancer Research Centre founder and Director,and BSMS researcher Simon Mitchell draws the symposium to a close with some exciting new funding initiatives for the SCRC going forward.

And a final bonus to cap off a great day, Laurence Pearl 🔥💚🚣‍♀️🛶♊️ presents the Sussex Cancer Research Centre Rising Star Award to our BCR-ABL warrior Jasmeen Oberoi!

Big thanks to Kostas Tzelepis from Cambridge Stem Cell Institute for visiting us at University of Sussex Sussex Life Sciences Sussex Blood Cancer Research and giving the final Biochemistry & Biomedicine @ University of Sussex seminar of the series. Fantastic talk with super exciting data and very grateful for the helpful input into several ongoing projects here.

Following on from our recent paper showing novel post-transcriptional roles for B-catenin in leukaemia cells, a very well done to Okan Sevim and Hyun Park for writing a superb review in Oncogene Journal summarising our current understanding of this field. nature.com/articles/s4138…

🗞️New publication alert🗞️ Drs Okan Sevim and Hyun Park from Sussex Life Sciences and BSMS in the Rhys Morgan review the current understanding around beta-catenin contribution to post-transcriptional regulation of gene expression out now at Oncogene Journal.

We are excited to announce a new round of funding available thanks to the Sussex Cancer Fund. The 2025 SCF:SCRC Pump-Priming Awards scheme is now open! Dealine: 4th August 2025 sussexcancer.org/news/new-scfsc… University of Brighton Sussex Life Sciences BSMS UHSussexResearch East Sussex Healthcare NHS Trust

I am honoured to be your ally in the fight against childhood #cancer!

We have 2 exciting roles in our team: Research Engagement Officer (p/t, hybrid £31,000 - £35,000 / year) Research Grants Officer (hybrid, £35,000 - £37,000 / year) More info here 👉🏻 shorturl.at/s8jYf Please share and get in touch if you’re interested ☺️

New paper led by Dr Eleanor Jayawant is on BlueSky 🎉 We review: - how computational biology is helping us understand lymphoma, - how machine learning and cell simulations make sense of vast amounts of data, - how models can personalise treatments to each person with lymphoma. portlandpress.com/biochemsoctran…

🗞️ New publication from the network 🗞️ Dr Dr Eleanor Jayawant is on BlueSky now working at the Prof Andrea Pepper Chris Pepper group in BSMS review the state of play in computational modelling of B-cell lymphomas, led by Simon Mitchell and now out at Portland Press Biochemical Society Transactions.

Today is also the day we launch our new research strategy focusing on accelerating progress through blood cancer research. You can read more here 👇 bit.ly/45XfkpN #beatingbloodcancer #bloodcancersymposium25

"We need to establish new targeted therapies that can replace or augment existing treatments" This afternoon we kicked off our treatment session with Prof Alex Tonks sharing his research investigating the role of ROS in AML. 👉bit.ly/4lyMY9Y #bloodcancersymposium25

Prof Michelle West spoke about her group's drug discovery work to target EBV blood cancer cells and leave healthy cells unscathed. 👉bit.ly/4nBMrG1 Because we need to develop new treatments that cure blood cancer for good. #bloodcancersymposium25

Very pleasing to see so many Sussex researchers in the new Blood Cancer UK Blood Cancer UK Research research strategy Accelerating Progress document!

Last month, final year PhD student Aimilia Vareli from Simon Mitchell lab in BSMS presented her research at the annual European Hematology Association congress 2025 in Milan, and has been awarded an EHA Research Mobility Grant to progress her work with collaborators at Harvard University university 👏

Nearing the end/completed your PhD? Interested in leukaemia research? Want to join a new and exciting PI as they establish their group at Sussex Life Sciences Then this 3y post doc post with newly minted MRC CDA Fellow & Blood Cancer UK Research funded Dr Jasmeen Oberoi could be for you 👇

New paper led by Aimilia Vareli out now. nature.com/articles/s4141… The lymphoma microenvironment stops BH3-mimetics from working. In vitro/vivo/silico, we find that inhibition of NFκB makes BH3-mimetics great again. 1/🧵 Sussex Blood Cancer Research Sussex Cancer Research Centre Leukaemia UK BSMS #UKRIFLF

Join us for the next Science Café hosted by Sussex Cancer Fund in partnership with the Macmillan Horizon Centre. To find out more information and to secure your space follow this link: sussexcancer.org/events We are looking forward to seeing you there 😊

🗞️ New network publication! 📰 Final year PhD student Aimilia Vareli in BSMS in Simon Mitchell lab publishes her doctoral studies in Springer Nature #CellDeathDisease showing inhibition of NFkB signalling increases sensitivity to BH3 mimetics in the lymphoma microenvironment.